Description

CJC-1295 is a tetrasubstituted 30-amino acid peptide hormone, primarily functioning as a releasing hormone (GHRH) analog.One of the advantages of CJC-1295 over traditional GHRH is its ability to bioconjugate with serum albumin, thus increasing its half-life and therapeutic window. It accomplishes this by using protecting groups around the amino acids of GHRH typically susceptible to enzymatic degradation.

The clinical research was ultimately successful for most research subjects. Ghrelin, released from the gut, which circulates and acts as a hunger hormone, has synergistic activity in the body with GHRH and also suppresses somatostatin to make way for the GHRH pulse.

Application

Research study participants for often cycle doses 2-3 times per day (ex: before breakfast, before bed, and after exertion) for a period up to several weeks. These cycles, or pulses are meant to closely mimic natural secretion of GH. For CJC 1295, dosing is less frequent since the half-life with DAC is up to 8 days. Therefore, the cycle for CJC 1295 with DAC calls for once weekly injections that result in an overall increase of secretion of GH. At this point, research does not show any significant advantage for one cycle over the other, so it is a matter of personal preference.

CJC-1925 is a sterile, non-pyrogenic, white lyophilized powder intended for subcutaneous or intramuscular injection, after reconstitution with sterile Water for Injection. CJC-1295 can be injected subcutaneously with an insulin syringe. Dose per injection: 2mg. Injections per vial: 1 X 2mg dosages Amount to Inject: If you have used 0.5ml of water for mixing then a 2mg dosage = 0.50ml (or 50 units on Insulin Syringe). If you have used 1ml of water then a 2mg dosage = 1ml (or 100 units). Sample Injection Frequency: 2mg injected once per week (due to its long half-life).